Anthony J. Polverino - 07 Jan 2022 Form 4 Insider Report for Zymeworks Inc.

Role
Chief Scientific Officer
Signature
/s/ Daniel Dex, Attorney-in-Fact
Issuer symbol
N/A
Transactions as of
07 Jan 2022
Net transactions value
+$1,032
Form type
4
Filing time
07 Jan 2022, 20:30:34 UTC
Previous filing
17 Dec 2021
Next filing
03 Feb 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ZYME Common Shares Award $1,032 +74 +0.2% $13.94* 36,407 07 Jan 2022 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Shares purchased pursuant to the Issuer's Amended and Restated Employee Stock Purchase Plan (ESPP) for the ESPP purchase period July 1, 2021 through December 31, 2021. In accordance with the ESPP, these shares were purchased at a price equal to 85% the closing price of the Issuer's common shares on December 31, 2021.